Background. Cardiovascular disease (CVD) is expected to contribute a large noncommunicable disease burden among human immunodeficiency virus (HIV)-infected people. We quantify the impact of prevention interventions on annual CVD burden and costs among HIV-infected people in the Netherlands.
As life expectancy of people living with human immunodeficiency virus (PLHIV) on effective combination antiretroviral therapy (cART) has improved [1] , human immunodeficiency virus (HIV) care focus is shifting from treatment and prevention of opportunistic infections to that of noncommunicable diseases (NCDs). Cardiovascular disease (CVD) is predicted to contribute one of the greatest NCD burdens among PLHIV on cART [2] . CVD prevalence and lifetime CVD risk appear to be higher in PLHIV than in HIV-uninfected controls [3] [4] [5] .
Although cardiovascular pathophysiology in the HIV context is not yet fully understood, likely mechanisms include complex interactions between traditional (eg, smoking), and HIV-related (eg, greater HIV-related inflammation linked to cART initiation at low CD4 counts) risk factors [6, 7] . Late HIV diagnosis and thus low CD4 count at cART initiation remains a problem in many European countries [8, 9] , despite new HIV guidelines recommending immediate cART initiation [10] . The prospective observational Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) Study carried out one of the most detailed analysis of modifiable CVD risk factors in >49 000 PLHIV from 11 cohorts across 212 clinics in Europe (including the Netherlands), Argentina, Australia, and the United States, combining them into a risk model predicting 5-year CVD risk [11] . These factors include smoking, total and high-density lipoprotein (HDL) cholesterol, systolic blood pressure, current CD4 count, current abacavir use, and cumulative exposure to protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors, suggesting these could be key targets for CVD prevention interventions in HIV care.
Prevention interventions will need to be firmly integrated into HIV care, and supported by evidence-based studies to effectively mitigate the emerging CVD burden, mortality risk, and impact on quality of life of PLHIV. Yet no studies have systematically compared the impact of different CVD prevention interventions on CVD burden in PLHIV, who are at CVD risk due to both traditional and HIV-related factors. We adapt an existing model of aging PLHIV on cART [2] to explore the impact of CVD prevention interventions and evaluate which one would maximize cardiovascular health. Interventions include HIV-related interventions (earlier HIV diagnosis and treatment and avoiding use of cART regimens with increased CVD risk) and traditional interventions (smoking cessation and intensified monitoring and drug treatment of hypertension and dyslipidemia).
METHODS

Model
We adapted an existing individual-based model of aging PLHIV in the Netherlands to generate detailed predictions of CVD [2] . Figure 1 shows the basic model structure, with technical details in Supplement 1. The model follows PLHIV on cART from 2010 to 2030, and probabilistically simulates clinical events (hypertension, dyslipidemia, diabetes, CVD, and death) and CVD treatment initiation. CVD includes myocardial infarction, stroke, coronary artery angioplasty, coronary bypass, carotid endarterectomy, and CVD-related death. The model is populated with all 8791 PLHIV on cART in care and registered with the Dutch national ATHENA (AIDS Therapy Evaluation in the Netherlands) cohort in 2010 aged ≥18 years, infected with HIV type 1 (HIV-1) only, cART naive at entry, who initiated cART from 1996 (baseline patients, Figure 1A ) by directly importing anonymized patient records into the model. Multiple imputation by chained equation was used to deal with missing data (MICE package, R Foundation for Statistical Computing, version 3.2.2), creating 20 imputed datasets. Values were assumed to be randomly missing, and extensive checks were carried out (Supplement 1).
The majority of ATHENA patients were virologically suppressed Dutch men who have sex with men, and median age was 44 years (Table 1 ). In 2010, 44.9% of moderate-to high-risk (HR, ie, predicted 5-year CVD risk ≥5%) patients with hypertension used antihypertensive medication, of whom 7.9% reached blood pressure levels of <120/80 mm Hg. In HR patients with dyslipidemia, 32.5% used lipid-lowering medication, of whom 61.1% reached a total/HDL cholesterol ratio of <5 (Table 1 ). All clinical definitions were based on European guidelines [10, 12] and consultation with cardiovascular specialists; hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, and/or use of antihypertensive medication; dyslipidemia was defined as total cholesterol >6.5 mmol/L (>250 mg/dL), total/HDL cholesterol ratio >5, and/or use of lipid-lowering medication; and CVD was based on clinical patient records. Each month, new simulated patients joined the modeled cohort representing cART initiators ( Figure 1A ). New patients' profiles were randomly selected from baseline patients, accounting for predicted changes in age up to 2030, CD4 cell count at cART initiation up to 2015, and changes in treatment guidelines in 2014 (use of integrase inhibitors for first-line cART) [2, 13, 14] .
CVD was simulated using a CVD risk equation, developed in PLHIV by the D:A:D study [11] . The equation accounts for demographic factors, traditional risk factors, and HIV-related risk factors to calculate 5-year CVD risk ( Figure 1B) . Constant risk was assumed within the 5-year timeframe to convert to monthly risks. CVD type was determined using the reported CVD distribution [11] .
The model accounts for a large number of interactions between demographic ( Figure 1C ), HIV-related ( Figure 1C ), therapy-related ( Figure 1C) , and clinical factors ( Figure 1C )-for example, the impact of age, sex, and clinical factors on mortality, or sex, age, use of lipid-lowering drugs, and cART regimen on cholesterol. For example, the model includes sex-specific monthly increments in blood pressure and cholesterol per 10-year age group based on the Dutch Doetinchem Cohort Study data [15] , cholesterol changes triggered by cART switches based on an extensive literature review, and blood pressure and cholesterol changes triggered by treatment based on ATHENA data (Supplement 1).
Model performance was evaluated via out-of-sample checks against 2010-2015 ATHENA data (Supplement 1). CVD burden was projected for 2010-2030, assuming demographic, epidemic, and clinical trends remain constant while accounting for predicted increasing CD4 count trends at cART initiation, and current levels in treatment of hypertension and dyslipidemia (baseline scenario). The impact of CVD prevention interventions was evaluated for 2017-2030, by comparing with baseline. Model results were based on the average of 100 simulations, consisting of running each of the 20 imputed dataset 5 times. The model was used to evaluate the following interventions: HIV-related interventions: In addition, we evaluated the effect of implementing all interventions jointly. For each intervention, we simulated the impact of reaching (1) all patients in care or HR patients only (except reducing "late" presenters, which was not evaluated for HR patients separately); or (2) 100% or 50% of patients successfully via the interventions. For example, the use of cART regimens with no known increased CVD risk at 50% successful implementation switched 50% of patients off ABC and PIs, while the remainder continued on their cART regimens, including ABC and PIs. For the intensified monitoring and treatment of hypertension and dyslipidemia at 50% successful implementation, all patients with hypertension and dyslipidemia were prescribed treatment, but only 50% reached target blood pressure and cholesterol levels, while the remainder reached blood pressure and cholesterol levels currently observed in ATHENA among patients on antihypertensive and lipid-lowering medication for ≥6 months (ie, some patients do not reach target levels and some do).
Economic Evaluation
An economic evaluation quantified the annual costs of CVD care in PLHIV between 2015 and 2030. In addition, annual CVD-related cost reductions were calculated for each intervention in 2017-2030. Economic evaluations accounted for lifetime CVD-related costs incurred; these comprised costs related to hospitalization, diagnostics, surgical procedures, and outpatient visits. Costs relating to intervention costs of medication were not included in the analysis. Cost sources included Dutch databases of healthcare, and literature, and costs were discounted at 3% per year (Supplement 1).
RESULTS
Annual CVD incidence is predicted to increase from 6.0 to 9.3 events per 1000 person-years in 2015-2030. Prevalence of ever having had CVD will increase from 2.7% to 11.4%, and the proportion of HR patients from 14.1% to 32.4%, between 2015 and 2030 ( Figure 2 ). All interventions tested are expected to reduce CVD burden by 2030. Traditional CVD interventions are predicted to have greater impact, and targeting HR patients would avert a majority of CVD cases (Figure 3 ). Earlier HIV diagnosis and treatment will have the smallest effect on CVD burden, preventing on average 0.1%-0.8% of CVD cases annually, assuming 50%-100% successful implementation. Avoiding the use of cART regimens with increased CVD risk could avert an average of 1.7%-3.7% of CVD cases annually in all patients and 0.3%-1.5% of CVD cases in HR patients, assuming 50%-100% successful implementation.
Smoking cessation could prevent an average of 6.0%-13.1% of CVD cases annually in all and 5.1%-12.6% of CVD cases in HR patients, assuming 50%-100% successful implementation.
Intensified monitoring and treatment of hypertension and dyslipidemia could have the greatest impact, averting an annual average of 17.0%-20.0% of CVD cases in all and 11.9%-15.9% of CVD cases in HR patients, assuming 50%-100% successful implementation.
Implementing all interventions simultaneously could avert an average of 20.2%-30.5% of CVD cases annually in all, and 13.1%-20.4% of CVD cases in HR patients, assuming 50%-100% successful implementation. Targeting HR patients only is likely to reduce the majority of CVD cases, particularly in smoking cessation, intensified monitoring and treatment of hypertension and dyslipidemia, and a joint intervention program (averting 96%, 80%, and 67%, respectively, compared with targeting all patients when assuming 100% successful implementation).
Annual CVD-related care costs for PLHIV are estimated to increase by 36%, from €471 000 in 2015 to €642 000 in 2030, in absence of additional CVD prevention interventions. This is despite HIV costs being predicted to decrease by 13% in the same period. Cumulative CVD-related costs in 2017-2030 could decrease by €63 000 (0.8%) with earlier HIV diagnosis and treatment, €308 000 (3.7%) by avoiding the use of cART regimens with increased CVD risk, €1 093 000 (13.1%) with smoking cessation, €1 670 000 (20.0%) with intensified monitoring and treatment of hypertension and dyslipidemia, and €2 539 000 (30.5%) with a joint intervention, assuming all patients are targeted 100% successfully. The reduction in CVDrelated costs is largely driven by HR patients. Cumulative CVDrelated costs, for example, could be reduced by €1 330 000 for intensified monitoring and treatment of hypertension and dyslipidemia, or 80% of the costs reduction achievable by targeting all PLHIV.
DISCUSSION
The growing burden of CVD among PLHIV in Europe will necessitate evidence-based prevention interventions to mitigate the impact on mortality, quality of life, clinical care, and healthcare budgets. The interventions considered in this study could jointly avert 30.5% of CVD events. Based on the output of this work, we recommend that CVD prevention policy in HIV care focus on traditional CVD prevention interventions, particularly intensifying the monitoring and successful treatment of hypertension and dyslipidemia. Such an intervention could most likely maximize cardiovascular health and reduce CVD-related costs among the set of CVD prevention interventions evaluated in this study. Targeting HR patients could avert the majority of CVD events and costs, averting 80% of CVD events and costs between 2017 and 2030, while targeting only 14.1%-32.4% (2015-2030) of PLHIV. Greater impact could be achieved by rolling out all interventions simultaneously and targeting all PLHIV, though likely at much higher expected programmatic costs.
Our findings are in line with preliminary work in PLHIV showing that dyslipidemia, hypertension, and smoking had much larger population attributable fractions for myocardial infarctions than HIV-related factors [16] . Intensification of monitoring and treatment of hypertension and dyslipidemia should be feasible, as measurement and management of blood pressure and cholesterol are standard in HIV care in the Netherlands. Current European and Dutch HIV guidelines recommend annual CVD risk assessment and treatment of hypertension (in patients with high CVD risk) and dyslipidemia (in patients with moderate to high CVD risk) [10, 17] . CVD risk assessment, utilizing for example the D:A:D equation, provides a simple and inexpensive tool to identify patients at elevated CVD risk. Yet, in 2010, 55%-68% of Dutch PLHIV at moderate to high CVD risk remain untreated and the majority did not reach optimal blood pressure or cholesterol levels (Table 1) . Suboptimal CVD risk management has been described in other settings [18, 19] . The proposed intervention would therefore focus on strengthening implementation of current guidelines, utilizing existing frameworks, and addressing gaps including undiagnosed and/or undertreated hypertension and dyslipidemia. Further research is needed to identify innovative strategies to support patients and healthcare providers in addressing these gaps, for which mobile phone-or web-based interventions might be promising tools. Smoking cessation is also predicted to substantially impact CVD burden. However, our assumption that 50%-100% of individuals will successfully cease to smoke is bold considering previous smoking cessation studies [20] [21] [22] [23] . In sensitivity analyses of more realistic estimates (ie, 10% smoking cessation) an average of 1.3% of CVD cases annually were averted in all PLHIV (Supplement 1). The low success rates of smoking cessation despite tailored interventions and the modest effect of a more realistic smoking cessation scenario on CVD burden means smoking cessation might not be the most effective and feasible CVD prevention intervention, despite its large theoretical impact.
Studies suggest that apart from their lipid-lowering properties, statins may also act as inflammation modulators [24] . In PLHIV, in whom immune activation/dysfunction can persist despite viral suppression, studies have shown that statins can reduce certain markers of inflammation and immune activation [25] as well as subclinical CVD [26] . The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial [27] may quantify the effectiveness of statins in preventing CVD in PLHIV, and inform further modeling studies in the field.
The model captures key factors involved in CVD pathophysiology. Extensive consultations with HIV and CVD physicians ensure the model incorporated key interactions between factors influencing CVD, ensuring the model captured the natural progression and aggregation of risk factors. The model created a direct representation of patients on cART in the Netherlands by directly importing patient records from a large national nonselective cohort, with parameter values based on large cohort studies and in-depth literature reviews. Extensive out-of-sample model checks and sensitivity analyses ensured that the model output was robust.
Despite these strengths, the study has a number of limitations. Some ATHENA data (eg, family history, smoking status) are collected at entry and not systematically time-updated. These and other variables (eg, cholesterol levels) can also be incomplete. We used multiple imputation to handle missing data, assuming variables were missing randomly; any heterogeneity could introduce bias of the results. Other interventions, including interventions targeting lifestyle and diet, were not evaluated. These risk factors are historically poorly collected in HIV cohorts and, although their importance is not disputed, consensus on their relative impact in the context of HIV is yet to be reached. As information about their relative impact becomes available, the model can be expanded to evaluate lifestyle interventions. In the absence of robust data in PLHIV, the model assumes that changes in blood pressure and cholesterol with age are the same in PLHIV and the general population. Although uncertainty around the superiority of various CVD risk equations remains [28] [29] [30] [31] , the D:A:D equation is likely among the superior tools for CVD risk prediction in PLHIV in Europe. It is the only one specifically developed in PLHIV, taking into account HIV-related factors. Yet the D:A:D equation does not distinguish between well and poorly controlled diabetes, nor between CVD risk of individual PIs (cumulative exposure to all PIs predicted CVD risk better than individual PIs, despite preliminary work describing that not all contemporarily used PIs are independently associated with an increased CVD risk [32] ). We were therefore unable to evaluate interventions centered around diabetes, or individual PIs. In addition, the D:A:D equation does not account for the longterm "fading" effect of stopping PIs or smoking on CVD risk, although we tested this in sensitivity analyses (Supplement 1), with results indicating that the model results remain robust. Additionally, we have presented the amount of CVD-related costs that could be averted if a program is 100% successful. It is important to note that these figures do not take into account any intervention-related costs, as these costs are too uncertain to estimate reliably for all interventions, as well as have impact beyond CVD. It is likely that many of these interventions will actually incur costs once programmatic costs are taken into account.
In the model, dyslipidemia was defined using total/HDL cholesterol ratio due to poorly collected low-density lipoprotein cholesterol data. While this might not fully represent management and recommendations in clinical care, we believe it to be a reasonable proxy. While 100% successful implementation scenarios served to illustrate the maximum intervention impact, even 50% successful implementation scenarios could be overly optimistic-for example, for smoking cessation, with well-documented difficulty of long-term smoking cessation in PLHIV [20] [21] [22] [23] .
While the focus of this study is on CVD prevention, it is likely that all interventions investigated in this study could have wider public health benefits. For example, smoking cessation could reduce the incidence of other diseases including lung cancer [33] , other malignancies [34] , chronic obstructive pulmonary disease [35] , and peripheral atherosclerotic disease [36] . Furthermore, reducing "late" presenters could prevent AIDS, HIV transmission, and NCDs other than CVD [7] . Systematically comparing these interventions with a wide public health perspective, including a cost-effectiveness analysis, could provide further evidence regarding policy development.
We expect the results to be generalizable to other settings with a long history of access to cART and a concentrated and mature HIV epidemic. It is not clear how the results would translate to epidemics with larger proportions of female patients. In settings such as sub-Saharan Africa, which is also seeing PLHIV aging [37] , there is an urgent need for country-specific estimates of future CVD and NCD burdens to identify effective intervention and best use of resources, particularly in light of overstretched healthcare systems.
The CVD burden among PLHIV on cART in Europe is increasing. Intensified monitoring plus successful treatment of hypertension and dyslipidemia in PLHIV is expected to be the most feasible intervention accompanied by the largest cardiovascular health benefit and could safeguard the quality of life of HIV-infected people.
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